Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
May 31, 2024 08:36 ET
|
Ocugen
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...
Ocugen to Present at BIO International Convention 2024
May 29, 2024 07:15 ET
|
Ocugen
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
May 28, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Global Cell and Gene Therapy (CGT) Supply Chain Software Markets, 2019-2023 & 2024-2035: Companies Enter Strategic Collaborations to Meet Growing Demand, Opportunities in Expanding Product Portfolios
May 22, 2024 05:03 ET
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Process Component, Type of...
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024 07:00 ET
|
Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Cell and Gene Therapy Business Outlook 2024: News Briefs and Analysis of the Science That will Shape Tomorrow's Business and Tracked Deals Between CAGT Companies
May 20, 2024 05:04 ET
|
Research and Markets
Dublin, May 20, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Business Outlook" report has been added to ResearchAndMarkets.com's offering. With thousands of potential therapies on the...
Cell and Gene Therapy Manufacturing Research Report 2024
May 15, 2024 09:07 ET
|
Research and Markets
Dublin, May 15, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
May 15, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with First Quarter 2024 Financial Results
May 14, 2024 08:00 ET
|
Ocugen
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market...